Literature DB >> 856020

Indirect mouse model for the evaluation of potential antiviral compounds: results with Venezuelan equine encephalomyelitis virus.

R W Kuehne, W L Pannier, E L Stephen.   

Abstract

An indirect mouse model was utilized to evaluate the antiviral activity of several compounds against Venezuelan equine encephalomyelitis (VEE) virus infection in mice. Mice were given various dosages of lysine-stabilized polyriboinosinic acid-polyribocytidylic acid, a tilorone analogue, kethoxal, or mepacrine before and/or shortly after receiving one of several dose levels of attenuated strain TC-83 VEE virus. Twenty-one days later, the same mice were rechallenged intracranially with virulent Trinidad donkey strain VEE virus. Susceptibility to rechallenge was interpreted as evidence of drug effectiveness in completely preventing the initial immunizing virus infection. In contrast, if a drug lacked antiviral effectiveness, the initial attenuated infection stimulated sufficient immunity to protect mice against the virulent rechallenge. Both of the interferon inducers, lysine-stabilized polyriboinosinic acid-polyribocytidylic acid and tilorone analogue 11,567, possessed significant (P < 0.01) antiviral activity based upon this indirect model, whereas mepacrine and kethoxal were inactive. Results using the indirect method were confirmed by using the conventional direct method for evaluating the effectiveness of potentially useful antiviral compounds. The indirect mouse model described should prove useful for studying drug efficacy against certain viruses that are lethal only by intracranial inoculation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856020      PMCID: PMC352050          DOI: 10.1128/AAC.11.4.683

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Response of irradiated mice to live-virus (TC-83) immunization.

Authors:  R O Spertzel; D E Hilmas; J R Brown; D W Mason
Journal:  Infect Immun       Date:  1975-03       Impact factor: 3.441

Review 2.  The continuing search for antiviral drugs.

Authors:  R A Buchnall
Journal:  Adv Pharmacol Chemother       Date:  1973

3.  Experiences in developing potential antiviral compounds.

Authors:  J R Dice; W A Rightsel; F M Schabel; I W McLean
Journal:  Ann N Y Acad Sci       Date:  1965-07-30       Impact factor: 5.691

4.  Interferon induction by, and antiviral effect of poly (rI)--poly (rC) in experimental viral infection.

Authors:  E B Tazulakhova; A S Novokhatsky; F I Yershov
Journal:  Acta Virol       Date:  1973-11       Impact factor: 1.162

5.  Interferon required for viral resistance induced by poly I.poly C.

Authors:  T W Schafer; R Z Lockart
Journal:  Nature       Date:  1970-05-02       Impact factor: 49.962

6.  A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates.

Authors:  H B Levy; G Baer; S Baron; C E Buckler; C J Gibbs; M J Iadarola; W T London; J Rice
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

7.  Evaluation of various analogues of tilorone hydrochloride against Venezuelan equine encephalitis virus in mice.

Authors:  R W Kuehne; W L Pannier; E L Stephen
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

8.  Interferon sensitivity of Venezuelan equine encephalomyelitis virus.

Authors:  G W Jordan
Journal:  Infect Immun       Date:  1973-06       Impact factor: 3.441

9.  Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero).

Authors:  J Desmyter; J L Melnick; W E Rawls
Journal:  J Virol       Date:  1968-10       Impact factor: 5.103

10.  Tilorone hydrochloride: mode of action.

Authors:  G D Mayer; R F Krueger
Journal:  Science       Date:  1970-09-18       Impact factor: 47.728

View more
  5 in total

1.  Rapid, non-invasive imaging of alphaviral brain infection: reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals.

Authors:  Michael Patterson; Allison Poussard; Katherine Taylor; Alexey Seregin; Jeanon Smith; Bi-Hung Peng; Aida Walker; Jenna Linde; Jennifer Smith; Milagros Salazar; Slobodan Paessler
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

Review 2.  Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology.

Authors:  Teck-Hui Teo; Fok-Moon Lum; Wendy W L Lee; Lisa F P Ng
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  In vivo imaging systems (IVIS) detection of a neuro-invasive encephalitic virus.

Authors:  Allison Poussard; Michael Patterson; Katherine Taylor; Alexey Seregin; Jeanon Smith; Jennifer Smith; Milagros Salazar; Slobodan Paessler
Journal:  J Vis Exp       Date:  2012-12-02       Impact factor: 1.355

4.  Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.

Authors:  M Kende; H W Lupton; W L Rill; H B Levy; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

5.  C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection.

Authors:  Justin G Julander; Ramona Skirpstunas; Venkatraman Siddharthan; Kristiina Shafer; Justin D Hoopes; Donald F Smee; John D Morrey
Journal:  Antiviral Res       Date:  2008-02-13       Impact factor: 5.970

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.